OncoMatch/Clinical Trials/NCT06421610
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
Is NCT06421610 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PITAC for malignant pleural effusion.
Treatment: PITAC — This study will monitor and evaluate patient and personnel safety and toxicity during the implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed treatment. Furthermore, this study will focus on Quality of Life questionnaires, LENT score, and evaluate pain and breathlessness using af visual analogue scales (VAS).
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: intrathoracic chemotherapy
Previous intrathoracic chemotherapy
Cannot have received: intrathoracic antibody treatment
Previous intrathoracic antibody treatment
Cannot have received: chemical pleurodesis
Previous...chemical pleurodesis
Lab requirements
Kidney function
Renal impairment, defined as GFR < 40 ml/min (Cockcroft-Gault Equation) [excluded]
Liver function
Impaired liver function defined as bilirubin ≥1.5 [excluded]
Cardiac function
Myocardial insufficiency, defined as NYHA class > 2 [excluded]
Renal impairment, defined as GFR < 40 ml/min (Cockcroft-Gault Equation); Myocardial insufficiency, defined as NYHA class > 2; Impaired liver function defined as bilirubin ≥1.5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify